Drug executive says regulatory obstacles delay new drugs, increase costs

07/16/2013 | BioSpectrum Asia

The actions of government regulatory agencies have contributed to declines in research productivity, discouraged investment and raised costs for the pharmaceutical industry throughout the world, according to Tony Alvarez, president of MSD KK in Japan, speaking at the in-Pharma Japan and Interphex Japan meetings in Tokyo. He alleged that such agencies, including the U.S. FDA, are deliberately blocking drug research and commercialization as a means of controlling costs.

View Full Article in:

BioSpectrum Asia

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC